-
Meloxicam for newborn calves: dose at birth, not surgery
Meloxicam for newborn calves is a postnatal adaptation treatment, not a surgical analgesic. In a 151-calf placebo-controlled trial, one subcutaneous dose of 0.5 mg/kg given within minutes of delivery produced higher vitality scores at 24 and 48 hours, with the gain concentrated in calves born with obstetric assistance. It did not correct perinatal acidosis. Why meloxicam is filed under the wrong job Most farms keep meloxicam wherever the disbudding iron lives. Castration, dehorning, lameness, anything that happens in a chute: the drug goes on the list, and in many markets the label reads the same way. That placement is a habit, not a pharmacology. Parturition is an inflammatory event in…
-
Meloxicam for Newborn Calves: What a 2026 Trial Found
Meloxicam for newborn calves: a 2026 placebo-controlled trial in 151 Holstein-Friesian calves found that a single subcutaneous injection of 0.5 mg/kg meloxicam given immediately after birth raised vitality scores at 24 and 48 hours. The benefit showed up mainly in calves born from difficult calvings. Meloxicam did not correct the acidosis that comes with birth, and heart rate variability proved too weak to predict which calves would struggle. The practical takeaway: target meloxicam to assisted calvings rather than dosing the whole herd. Why newborn calf vitality matters more than it looks The first 48 hours of a calf’s life decide a large share of its future. Calves that stand slowly,…
